- Standort
-
Deutsche Nationalbibliothek Frankfurt am Main
- ISSN
-
1776-260X
- Umfang
-
Online-Ressource
- Sprache
-
Englisch
- Anmerkungen
-
online resource.
- Erschienen in
-
Correction to: Durvalumab: A Review in Extensive-Stage SCLC ; volume:17 ; number:1 ; day:6 ; month:12 ; year:2021 ; pages:91 ; date:1.2022
Targeted oncology ; 17, Heft 1 (6.12.2021), 91, 1.2022
- Urheber
-
Al-Salama, Zaina T.
- Beteiligte Personen und Organisationen
-
SpringerLink (Online service)
- DOI
-
10.1007/s11523-021-00863-w
- URN
-
urn:nbn:de:101:1-2022050509425653529794
- Rechteinformation
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Letzte Aktualisierung
-
15.08.2025, 07:30 MESZ
Datenpartner
Dieses Objekt wird bereitgestellt von:
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Beteiligte
- Al-Salama, Zaina T.
- SpringerLink (Online service)
Ähnliche Objekte (12)
Durvalumab: A Review in Extensive-Stage SCLC
Paraneoplastic myelitis associated with durvalumab treatment for extensive-stage small cell lung cancer
Correction to: Durvalumab: A Review in Advanced Biliary Tract Cancer
First-line durvalumab plus platinum-etoposide in extensive-stage small-cell lung cancer: CASPIAN Japan subgroup analysis
First-line atezolizumab/durvalumab plus platinum–etoposide combined with radiotherapy in extensive-stage small-cell lung cancer
Curative-Intent Treatment with Durvalumab in Early-Stage Cancers
Cost-Effectiveness Analysis of Atezolizumab Versus Durvalumab as First-Line Treatment of Extensive-Stage Small-Cell Lung Cancer in the USA
Arzneimittel Profil Durvalumab
Longitudinal extensive transverse myelitis after chemoradiation therapy with durvalumab, a rare complication: case report
Durvalumab: A Review in Advanced Biliary Tract Cancer
Author Correction: Neoadjuvant durvalumab plus radiation versus durvalumab alone in stages I–III non-small cell lung cancer: survival outcomes and molecular correlates of a randomized phase II trial
Durvalumab Plus Tremelimumab in Solid Tumors: A Systematic Review
Durvalumab: A Review in Extensive-Stage SCLC
Paraneoplastic myelitis associated with durvalumab treatment for extensive-stage small cell lung cancer
Correction to: Durvalumab: A Review in Advanced Biliary Tract Cancer
First-line durvalumab plus platinum-etoposide in extensive-stage small-cell lung cancer: CASPIAN Japan subgroup analysis
First-line atezolizumab/durvalumab plus platinum–etoposide combined with radiotherapy in extensive-stage small-cell lung cancer
Curative-Intent Treatment with Durvalumab in Early-Stage Cancers
Cost-Effectiveness Analysis of Atezolizumab Versus Durvalumab as First-Line Treatment of Extensive-Stage Small-Cell Lung Cancer in the USA
Arzneimittel Profil Durvalumab
Longitudinal extensive transverse myelitis after chemoradiation therapy with durvalumab, a rare complication: case report
Durvalumab: A Review in Advanced Biliary Tract Cancer
Author Correction: Neoadjuvant durvalumab plus radiation versus durvalumab alone in stages I–III non-small cell lung cancer: survival outcomes and molecular correlates of a randomized phase II trial
Durvalumab Plus Tremelimumab in Solid Tumors: A Systematic Review
Durvalumab: A Review in Extensive-Stage SCLC
Paraneoplastic myelitis associated with durvalumab treatment for extensive-stage small cell lung cancer
Correction to: Durvalumab: A Review in Advanced Biliary Tract Cancer
First-line durvalumab plus platinum-etoposide in extensive-stage small-cell lung cancer: CASPIAN Japan subgroup analysis
First-line atezolizumab/durvalumab plus platinum–etoposide combined with radiotherapy in extensive-stage small-cell lung cancer
Curative-Intent Treatment with Durvalumab in Early-Stage Cancers
Cost-Effectiveness Analysis of Atezolizumab Versus Durvalumab as First-Line Treatment of Extensive-Stage Small-Cell Lung Cancer in the USA
Arzneimittel Profil Durvalumab
Longitudinal extensive transverse myelitis after chemoradiation therapy with durvalumab, a rare complication: case report
Durvalumab: A Review in Advanced Biliary Tract Cancer
Author Correction: Neoadjuvant durvalumab plus radiation versus durvalumab alone in stages I–III non-small cell lung cancer: survival outcomes and molecular correlates of a randomized phase II trial